QIAGEN (NYSE:QGEN) Downgraded to “Hold” Rating by Wall Street Zen

Wall Street Zen lowered shares of QIAGEN (NYSE:QGEN) from a buy rating to a hold rating in a research report report published on Friday.

A number of other equities research analysts have also recently issued reports on the stock. Bank of America increased their target price on shares of QIAGEN from $50.00 to $53.00 and gave the stock a “buy” rating in a research report on Thursday, June 26th. Cowen reiterated a “hold” rating on shares of QIAGEN in a research report on Thursday, August 7th. Barclays set a $53.00 target price on shares of QIAGEN and gave the stock an “overweight” rating in a research note on Thursday. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of QIAGEN in a research note on Saturday, September 27th. Finally, UBS Group boosted their target price on shares of QIAGEN from $48.00 to $50.00 and gave the stock a “neutral” rating in a research note on Thursday, August 7th. Three research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $49.40.

QIAGEN Trading Up 1.3%

Shares of QIAGEN stock opened at $46.83 on Friday. The stock has a market capitalization of $10.41 billion, a P/E ratio of 27.67, a price-to-earnings-growth ratio of 2.44 and a beta of 0.66. The company has a quick ratio of 1.35, a current ratio of 1.61 and a debt-to-equity ratio of 0.25. The company has a 50-day simple moving average of $47.43 and a 200 day simple moving average of $45.24. QIAGEN has a 12-month low of $37.63 and a 12-month high of $51.88.

QIAGEN (NYSE:QGEN) last announced its earnings results on Tuesday, August 5th. The company reported $0.60 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.60. The business had revenue of $533.54 million during the quarter, compared to analysts’ expectations of $523.97 million. QIAGEN had a net margin of 18.30% and a return on equity of 14.77%. The firm’s revenue for the quarter was up 7.7% on a year-over-year basis. During the same quarter last year, the company posted $0.55 EPS. QIAGEN has set its Q3 2025 guidance at 0.580- EPS. FY 2025 guidance at 2.350-2.350 EPS. Research analysts expect that QIAGEN will post 2.26 earnings per share for the current fiscal year.

Institutional Investors Weigh In On QIAGEN

Institutional investors and hedge funds have recently modified their holdings of the business. SVB Wealth LLC bought a new stake in shares of QIAGEN during the first quarter worth approximately $31,000. MAI Capital Management raised its stake in shares of QIAGEN by 998.9% during the second quarter. MAI Capital Management now owns 978 shares of the company’s stock worth $47,000 after buying an additional 889 shares during the last quarter. Farther Finance Advisors LLC raised its stake in shares of QIAGEN by 400.5% during the second quarter. Farther Finance Advisors LLC now owns 1,061 shares of the company’s stock worth $51,000 after buying an additional 849 shares during the last quarter. Allworth Financial LP raised its stake in shares of QIAGEN by 260.1% during the second quarter. Allworth Financial LP now owns 1,102 shares of the company’s stock worth $53,000 after buying an additional 796 shares during the last quarter. Finally, Cullen Frost Bankers Inc. raised its stake in shares of QIAGEN by 13,144.4% during the second quarter. Cullen Frost Bankers Inc. now owns 1,192 shares of the company’s stock worth $57,000 after buying an additional 1,183 shares during the last quarter. 70.00% of the stock is owned by institutional investors.

About QIAGEN

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.